248 related articles for article (PubMed ID: 11268435)
21. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
22. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer.
Joensuu H; Holli K; Oksanen H; Valavaara R
Breast Cancer Res Treat; 2000 Oct; 63(3):225-34. PubMed ID: 11110056
[TBL] [Abstract][Full Text] [Related]
23. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
Saarto T; Blomqvist C; Ehnholm C; Taskinen MR; Elomaa I
J Clin Oncol; 1996 Feb; 14(2):429-33. PubMed ID: 8636753
[TBL] [Abstract][Full Text] [Related]
24. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
[TBL] [Abstract][Full Text] [Related]
25. Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention.
Curtis MG
Drug Saf; 2001; 24(14):1039-53. PubMed ID: 11735660
[TBL] [Abstract][Full Text] [Related]
26. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
27. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Garrone O; Bertelli G; Principe E; Lewis PD; Occelli M; Miraglio E; Merlano MC
Tumori; 2014; 100(6):620-4. PubMed ID: 25688495
[TBL] [Abstract][Full Text] [Related]
28. Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging.
Ochi J; Hayakawa K; Moriguchi Y; Urata Y; Yamamoto A; Kawai K
Jpn J Radiol; 2010 Jul; 28(6):430-6. PubMed ID: 20661693
[TBL] [Abstract][Full Text] [Related]
29. High-dose toremifene vs tamoxifen in postmenopausal advanced breast cancer.
Gershanovich M; Hayes DF; Ellmén J; Vuorinen J
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):29-36. PubMed ID: 9165504
[TBL] [Abstract][Full Text] [Related]
30. Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.
Wiseman LR; Goa KL
Drugs; 1997 Jul; 54(1):141-60. PubMed ID: 9211086
[TBL] [Abstract][Full Text] [Related]
31. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
32. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.
Kieback DG; Harbeck N; Bauer W; Hadji P; Weyer G; Menschik T; Hasenburg A
Gynecol Oncol; 2010 Dec; 119(3):500-5. PubMed ID: 20832103
[TBL] [Abstract][Full Text] [Related]
33. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
Gianni L; Gelber S; Ravaioli A; Price KN; Panzini I; Fantini M; Castiglione-Gertsch M; Pagani O; Simoncini E; Gelber RD; Coates AS; Goldhirsch A
Eur J Cancer; 2009 Mar; 45(4):561-71. PubMed ID: 19062268
[TBL] [Abstract][Full Text] [Related]
34. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.
Gianni L; Panzini I; Li S; Gelber RD; Collins J; Holmberg SB; Crivellari D; Castiglione-Gertsch M; Goldhirsch A; Coates AS; Ravaioli A;
Cancer; 2006 Feb; 106(3):505-13. PubMed ID: 16369994
[TBL] [Abstract][Full Text] [Related]
35. High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB).
Perry JJ; Berry DA; Weiss RB; Hayes DM; Duggan DB; Henderson IC
Breast Cancer Res Treat; 1995; 36(1):35-40. PubMed ID: 7579504
[TBL] [Abstract][Full Text] [Related]
36. Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53.
Rahko E; Blanco G; Bloigu R; Soini Y; Talvensaari-Mattila A; Jukkola A
Breast; 2006 Feb; 15(1):69-75. PubMed ID: 16005229
[TBL] [Abstract][Full Text] [Related]
37. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
38. Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study.
Shien T; Doihara H; Sato N; Anan K; Komaki K; Miyauchi K; Yanagita Y; Fujisawa T; Mitsuyama S; Kanbayashi C; Kusama M; Kimura M; Jinno H; Sano M; Ikeda T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):269-275. PubMed ID: 29196963
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer.
Gylling H; Pyrhönen S; Mäntylä E; Mäenpää H; Kangas L; Miettinen TA
J Clin Oncol; 1995 Dec; 13(12):2900-5. PubMed ID: 8523053
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen versus toremifene in the adjuvant treatment of breast cancer.
Holli K;
Eur J Cancer; 2002 Nov; 38 Suppl 6():S37-8. PubMed ID: 12409068
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
